HEALTH● LOW2h ago · Oct 26, 2026, 10:06 PM
Pfizer Talzenna/Xtandi combo approved for earlier prostate cancer setting
Seeking Alpha Tech · global
A combination therapy involving Pfizer's Talzenna and Xtandi has received approval for use in an earlier stage of prostate cancer treatment. This represents a new development in oncology for patients with this condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH46m agoGovernment turning to AI to solve the acknowledged problem of medication shortagesMexico News DailyHEALTH1h agoPsychology says there are people who can converse with strangers, participate in meetings, and function without difficulty in social situations, but find it difficult to maintain close friendships. Although they know many people, they rarely feel that these relationships reach profoundness.ClarínHEALTH2h agoEbola: Why Nigeria evacuated patient to Switzerland – NCDCPremium TimesHEALTH3h agoAmid alleged liquor deaths in Madhya Pradesh’s Dewas, police nab 10 for illicit tradeThe Hindu